Moseley Investment Management Inc. bought a new stake in Eli Lilly And Co (NYSE:LLY) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 2,412 shares of the company’s stock, valued at approximately $313,000.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Athena Capital Advisors LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth approximately $26,000. Wakefield Asset Management LLLP acquired a new stake in Eli Lilly And Co during the 4th quarter worth approximately $27,000. Trust Department MB Financial Bank N A lifted its position in Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after acquiring an additional 82 shares during the period. Larson Financial Group LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth approximately $29,000. Finally, Acima Private Wealth LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth approximately $33,000. 79.42% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Donald A. Zakrowski sold 1,000 shares of Eli Lilly And Co stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $128.50, for a total transaction of $128,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of Eli Lilly And Co stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the sale, the vice president now directly owns 110,300 shares in the company, valued at $12,874,216. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 246,112 shares of company stock worth $31,888,255. Corporate insiders own 0.11% of the company’s stock.
A number of analysts have weighed in on LLY shares. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. JPMorgan Chase & Co. started coverage on Eli Lilly And Co in a research report on Tuesday, March 12th. They set an “overweight” rating and a $140.00 price objective for the company. Guggenheim cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price objective for the company. in a research report on Thursday, April 11th. Credit Suisse Group set a $121.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Friday, March 22nd. Finally, UBS Group started coverage on Eli Lilly And Co in a research report on Wednesday, March 20th. They set a “buy” rating and a $74.51 price objective for the company. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $119.99.
LLY stock opened at $115.24 on Thursday. Eli Lilly And Co has a 52-week low of $84.64 and a 52-week high of $132.13. The company has a debt-to-equity ratio of 5.50, a quick ratio of 0.85 and a current ratio of 1.12. The firm has a market cap of $108.94 billion, a PE ratio of 20.76, a price-to-earnings-growth ratio of 1.99 and a beta of 0.27.
Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The firm had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.12 billion. During the same quarter last year, the firm earned $1.31 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, equities research analysts predict that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Friday, May 17th were given a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.24%. The ex-dividend date was Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: What is total return in investing?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.